Tests heat-based ablation for small, low-risk thyroid cancer
Tests radiofrequency ablation, a heat treatment, in adults with small thyroid cancer.
Plain-language title generated from the registry record
Registry title: The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer
Key facts
- Where
- Toronto, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06929650, who can take part
Where in Canada
- University Health NetworkToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT06929650
- Record updated
- 16 April 2025
- Original description
The goal of this clinical trial is to test radiofrequency ablation (RFA) in thyroid cancers ≤2 cm in diameter. The main question it aims to answer is:Read full original descriptionShow less
Thermo-Ablation With Radiofrequency Medical Technologies to Treat Thyroid Cancers
The goal of this clinical trial is to test radiofrequency ablation (RFA) in thyroid cancers ≤2 cm in diameter. The main question it aims to answer is:
• What is the feasibility of RFA use for low-risk thyroid cancers (≤2 cm)?
Participants will undergo a set of pre-procedural scans of the target thyroid nodule and undergo the RFA procedure/intervention. Then, participants will partake in three follow-up appointments at 4 weeks, 6 months, and 12 months post-procedure as per standard of care.
Inclusion: Patients with:; Nodule less than or equal to 2cm in size; Specifically: Bethesda 5/6; Their age is ≥18 years and ≤100 years; Able to provide written consent; Able to attend required follow-ups as per the protocol.
Exclusion: Previously treated for thyroid cancer; Any concern for invasive or metastatic thyroid cancer; Patients <18 years old; Pregnant women.